Unknown

Dataset Information

0

The impact of order with radiation therapy in stage IIIA pathologic N2 NSCLC patients: a population-based study.

ABSTRACT: BACKGROUND:The aim of this study was to investigate the optimal order of radiation therapy in patients affected by stage IIIA pathologic N2 (IIIA/N2) non-small-cell lung cancer (NSCLC) and to identify its potential risk factors. METHODS:17,654 (8786 men and 8868 women) diagnosed with NSCLC stage IIIA-N2 from 2004 to 2015 patients were identified in the Surveillance, Epidemiology, and End Results (SEER) database. Among the relevant clinical parameters, we evaluated overall survival (OS), lung cancer-specific survival (LCSS) and other variables such as age, sex and tumor size in patients who were treated with different combinations of surgery and radiotherapy strategies. RESULTS:We discovered that surgery benefit in younger IIIA/N2 NSCLC patients (age???75), and compared with surgery only, preoperative radiotherapy significantly improved the survival rate most (p??75?years old, who underwent postoperative radiotherapy (PORT) had the highest survival rate (p?

SUBMITTER: Duan H 

PROVIDER: S-EPMC7448510 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

The impact of order with radiation therapy in stage IIIA pathologic N2 NSCLC patients: a population-based study.

Duan Hongxia H   Liang Long L   Xie Shuanshuan S   Wang Changhui C  

BMC cancer 20200826 1

<h4>Background</h4>The aim of this study was to investigate the optimal order of radiation therapy in patients affected by stage IIIA pathologic N2 (IIIA/N2) non-small-cell lung cancer (NSCLC) and to identify its potential risk factors.<h4>Methods</h4>17,654 (8786 men and 8868 women) diagnosed with NSCLC stage IIIA-N2 from 2004 to 2015 patients were identified in the Surveillance, Epidemiology, and End Results (SEER) database. Among the relevant clinical parameters, we evaluated overall survival  ...[more]

Similar Datasets

Unknown Choice of postoperative radiation for stage IIIA pathologic N2 non-small cell lung cancer: impact of metastatic lymph node number.
| S-EPMC5747172 | biostudies-literature
Unknown Molecular Markers for Long-term Survival in Stage IIIA (N2) NSCLC Patients.
| S-EPMC8717953 | biostudies-literature
Unknown Lobectomy Versus Sublobectomy in Stage IIIA/N2 Non-Small Cell Lung Cancer: A Population-Based Study.
| S-EPMC8696201 | biostudies-literature
Unknown PLNR?20% may be a benefit from PORT for patients with IIIA-N2 NSCLC: a large population-based study.
| S-EPMC6152602 | biostudies-literature
Unknown Adjuvant therapy in stage IIIA-N2 non-small cell lung cancer after neoadjuvant concurrent chemoradiotherapy followed by surgery.
| S-EPMC7330356 | biostudies-literature
Unknown Resectable IIIA-N2 Non-Small-Cell Lung Cancer (NSCLC): In Search for the Proper Treatment.
| S-EPMC7465235 | biostudies-literature
Unknown Advances in multimodal treatment for stage IIIA-N2 non-small cell lung cancer.
| S-EPMC8177852 | biostudies-literature
Unknown Cancer Associated Fibroblasts in Stage I-IIIA NSCLC: Prognostic Impact and Their Correlations with Tumor Molecular Markers.
| S-EPMC4529239 | biostudies-literature
Unknown Clinical significance of DNA damage response mutations in stage I and stage IIIa NSCLC.
| S-EPMC10643798 | biostudies-literature
Unknown Neoadjuvant Savolitinib targeted therapy stage IIIA-N2 primary lung adenocarcinoma harboring <i>MET</i> Exon 14 skipping mutation: A case report.
| S-EPMC9424904 | biostudies-literature